^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    nemvaleukin alfa (ALKS 4230)

    i
    Company:
    Mural Oncology
    Drug class:
    IL-2R agonist
    Related drugs:
    Apply
    Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (NCT04592653)
    Phase 1/2
    Mural Oncology, Inc
    Active, not recruiting
    Last update posted :
    06/07/2024
    Initiation :
    09/30/2020
    Primary completion :
    07/01/2024
    Completion :
    12/01/2024
    MSI • NCAM1
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • nemvaleukin alfa (ALKS 4230)
    Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6 (NCT04830124)
    Phase 2
    Mural Oncology, Inc
    Recruiting
    Last update posted :
    03/20/2024
    Initiation :
    05/27/2021
    Primary completion :
    03/01/2024
    Completion :
    09/01/2025
    BRAF
    |
    BRAF mutation
    |
    nemvaleukin alfa (ALKS 4230)